| Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic MN Samtani, A Vermeulen, K Stuyckens Clinical pharmacokinetics 48 (9), 585-600, 2009 | 215 | 2009 |
| The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials N Raghavan, MN Samtani, M Farnum, E Yang, G Novak, M Grundman, ... Alzheimer's & Dementia 9 (1), S21-S31, 2013 | 115 | 2013 |
| An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative MN Samtani, M Farnum, V Lobanov, E Yang, N Raghavan, A DiBernardo, ... The Journal of Clinical Pharmacology 52 (5), 629-644, 2012 | 110 | 2012 |
| Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia S Gopal, C Gassmann-Mayer, J Palumbo, MN Samtani, R Shiwach, ... Current medical research and opinion 26 (2), 377-387, 2010 | 107 | 2010 |
| Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: a phase‐1, single‐dose, randomized, open‐label study P Ravenstijn, B Remmerie, A Savitz, MN Samtani, I Nuamah, CT Chang, ... the journal of clinical pharmacology 56 (3), 330-339, 2016 | 95 | 2016 |
| Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose‐ranging … M Alba, J Yee, ME Frustaci, MN Samtani, P Fleck Clinical Obesity 11 (2), e12432, 2021 | 94 | 2021 |
| Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data MN Samtani, S Gopal, C Gassmann-Mayer, L Alphs, JM Palumbo CNS drugs 25 (10), 829-845, 2011 | 94 | 2011 |
| Quantifying the pathophysiological timeline of Alzheimer's disease. E Yang, M Farnum, V Lobanov, T Schultz, N Raghavan, MN Samtani, ... Journal of Alzheimer's Disease 26 (4), 2011 | 84 | 2011 |
| Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients MN Samtani, R Flamm, K Kaniga, P Nandy Antimicrobial agents and chemotherapy 54 (6), 2360-2364, 2010 | 79 | 2010 |
| Betamethasone pharmacokinetics after two prodrug formulations in sheep: implications for antenatal corticosteroid use MN Samtani, M Lohle, A Grant, PW Nathanielsz, WJ Jusko Drug metabolism and disposition 33 (8), 1124-1130, 2005 | 77 | 2005 |
| Disease progression model for clinical dementia rating–sum of boxes in mild cognitive impairment and Alzheimer’s subjects from the Alzheimer’s disease Neuroimaging initiative MN Samtani, N Raghavan, G Novak, P Nandy, VA Narayan Neuropsychiatric disease and treatment, 929-952, 2014 | 76 | 2014 |
| A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia D Coppola, Y Liu, S Gopal, B Remmerie, MN Samtani, DW Hough, ... BMC psychiatry 12 (1), 26, 2012 | 75 | 2012 |
| Comparison of dexamethasone pharmacokinetics in female rats after intravenous and intramuscular administration MN Samtani, WJ Jusko Biopharmaceutics & drug disposition 26 (3), 85-91, 2005 | 74 | 2005 |
| Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with type 2 diabetes mellitus and obesity: a randomized dose‐ranging study NA Di Prospero, J Yee, ME Frustaci, MN Samtani, M Alba, P Fleck Clinical Obesity 11 (2), e12433, 2021 | 63 | 2021 |
| Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes MN Samtani, N Raghavan, Y Shi, G Novak, M Farnum, V Lobanov, ... British journal of clinical pharmacology 75 (1), 146-161, 2013 | 58 | 2013 |
| Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients P Nandy, MN Samtani, R Lin Antimicrobial agents and chemotherapy 54 (6), 2354-2359, 2010 | 58 | 2010 |
| Cerebrospinal fluid biomarkers for Alzheimer’s disease: a view of the regulatory science qualification landscape from the coalition against major diseases CSF biomarker team SP Arnerić, R Batrla-Utermann, L Beckett, T Bittner, K Blennow, L Carter, ... Journal of Alzheimer’s disease 55 (1), 19-35, 2016 | 54 | 2016 |
| Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid Aβ1-42 Level QS Li, AR Parrado, MN Samtani, VA Narayan, ... PloS one 10 (8), e0134000, 2015 | 50 | 2015 |
| Quantification of dexamethasone and corticosterone in rat biofluids and fetal tissue using highly sensitive analytical methods: assay validation and application to a … MN Samtani, WJ Jusko Biomedical Chromatography 21 (6), 585-597, 2007 | 50 | 2007 |
| Stability of dexamethasone sodium phosphate in rat plasma MN Samtani, WJ Jusko International journal of pharmaceutics 301 (1-2), 262-266, 2005 | 46 | 2005 |
